Biotech financing: Will ImaRx break the IPO slump?
(UPDATED: See below.)
It’s been a long, barren summer for biotech IPOs, but ImaRx, the blood-clot company we featured here, finally managed to bull its way into the public markets. The company, which withdrew an earlier $75 million IPO and lowered its offering price on the current… Continue Reading
Jazz Pharma takes it on the chin, raises less-than-expected $108M in IPO
Reuters is reporting that Jazz Pharmaceuticals, maker of the controversial drug Xyrem, priced its six million IPO shares at $18 apiece — roughly 30% below its earlier, most optimistic hopes. Just this morning, Jazz lowered its expected range to $20 to $21, down from an… Continue Reading
Jazz slashes expected IPO price, follows “date rape” controversy
Jazz Pharmaceuticals, the generally unexciting specialty-pharmaceutical maker that hoped to raise $179.4 million in an IPO, has collided with reality.
The Palo Alto, Calif. company today slashed its expected IPO price by a fifth.
We’ve written before about Jazz and its wildly overrated strategy of salvaging poorly… Continue Reading
Jazz Pharma ratchets down IPO hopes amid drug controversy
(UPDATED: See below.) Jazz Pharmaceuticals, the generally unexciting specialty-pharmaceutical maker that had hoped to raise $179.4 million in an IPO, has collided with reality.
The company today lowered its expected IPO take to a maximum of $144.9 million, a drop of almost 20 percent, based on an expected… Continue Reading
Jazz Pharmaceuticals shoots for $179M IPO with me-too drugs
Jazz Pharmaceuticals, a Palo Alto, Calif., outfit that licenses and acquires drugs from other companies, said it hopes to raise up to $179.4 million in a 6.9 million share offering — all based on a stable of unexciting drug retreads.
According to its SEC filing, Jazz… Continue Reading
Jazz Pharmaceuticals files for gutsy $172M IPO
Jazz Pharmaceuticals, a Palo Alto, Calif. company that seeks to license drugs from other companies, buy other drug companies and develop its own drugs, all in the area neurology and psychiatry, has filed for a $172.5 million IPO.
Here is its filing. It is four years… Continue Reading